Bioqual - BIOQ STOCK NEWS

BIOQUAL (OTC Pink: BIOQ) has released its unaudited financial results for the third quarter of fiscal year 2025. The company reported quarterly revenue of $14.03 million, down from $15.34 million in the same period last year.

For the nine months ended February 28, 2025, revenue decreased to $37.20 million from $46.79 million year-over-year. The company posted a quarterly net income of $936,030 ($1.05 per share), compared to $275,026 ($0.31 per share) in Q3 2024. However, for the nine-month period, BIOQUAL recorded a net loss of $951,497 (-$1.06 per share) versus a net income of $1.66 million ($1.86 per share) in the previous year.

BIOQUAL (BIOQ) has reported its unaudited financial results for the second quarter of fiscal year 2025, showing significant declines across key metrics. Revenue decreased to $23.17 million for the six months ended November 30, 2024, down from $31.45 million in the same period of 2023. The company reported a net loss of $1.89 million for the six-month period, compared to a net income of $1.38 million in the previous year.

For the three-month period ended November 30, 2024, revenue was $11.40 million, down from $15.87 million, with a net loss of $1.21 million compared to a net income of $484,661 in the prior year. Basic and diluted earnings per share declined to ($2.11) for the six-month period, compared to $1.55 in 2023.

BIOQUAL (BIOQ) announced changes to its Board of Directors. Charles Francisco, who served as a director since 1992, retired effective December 31, 2024, at age 85. His retirement was not related to any disagreements with Board policies or practices.

Amy Johnston joined the Board on December 31, 2024, maintaining the same number of directors. Johnston brings over 30 years of healthcare and biotech industry experience. Her notable achievements include leading commercial biotech teams, supporting a Hepatitis C compound launch that achieved $1B in first-year sales, and successfully increasing a utility company's revenue from $10 million to $25 million during the pandemic. She holds dual Bachelor's degrees in Government and English and a Master's in Secondary English Education from the College of William and Mary.

BIOQUAL, Inc. (OTC Pink: BIOQ) has released its unaudited financial results for the first quarter of fiscal year 2025, ending August 31, 2024. The company reported a significant decline in performance compared to the same period last year:

- Revenue decreased to $11,770,482 from $15,578,922 in Q1 FY2024
- Income before income tax shifted to a loss of $931,825 from a profit of $1,241,183
- Net income turned to a loss of $675,325 from a profit of $899,483
- Basic and diluted earnings per share of common stock dropped to ($0.76) from $1.01

The weighted average number of shares outstanding remained stable at 894,416 for basic earnings per share and 894,405 for diluted earnings per share.

BIOQUAL (BIOQ) has announced its twenty-third dividend declaration. The company's Board of Directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024. The dividend is payable on October 28, 2024.

This announcement demonstrates BIOQUAL's commitment to returning value to its shareholders. The dividend declaration suggests the company's financial stability and confidence in its future performance. However, it's important to note that past performance does not guarantee future results, and investors should consider their individual financial situations before making investment decisions.

BIOQUAL, Inc. (OTC Pink: BIOQ) has released its financial results for Fiscal Year 2024. The company reported:

• Revenue of $58,590,949, down from $62,663,804 in 2023
• Income Before Income Tax of $476,447, compared to $1,133,242 in 2023
• Net Income of $483,481, a decrease from $835,548 in 2023
• Basic and Diluted Earnings per Share of Common Stock both at $0.54, down from $0.93 in 2023

The Weighted Average Number of Shares Outstanding for both Basic and Diluted Earnings Per Share remained constant at 894,416.

BIOQUAL, Inc. (OTC: BIOQ) has announced a 10% reduction in workforce effective September 9, 2024, as a cost-cutting measure in response to decreased revenue and profitability over the past year. The company attributes this decline to a significant drop in demand for its services in the post-COVID-19 environment, following the development of vaccines and therapeutics.

Despite this workforce reduction, BIOQUAL does not anticipate any impact on its current services or future business prospects. The company aims to realign its cost structure to adapt to the changing market conditions while maintaining its operational capabilities.

BIOQUAL, Inc. (BIOQ) presents unaudited financial results for the third quarter of fiscal year 2024, showing revenue of $46,792,353 for nine months ended February 29, 2024. Net income increased to $1,659,170 compared to the same period last year. Income before income tax also saw growth. Visit www.bioqual.com for more details.

BIOQUAL, Inc. (BIOQ) reports a slight decrease in revenue for the six months ended November 30, 2023, compared to the same period in 2022. The company also experienced a decline in income before income tax and net income. Basic and diluted earnings per share of common stock also decreased. The unaudited second quarter results can be found on the company's website. Forward-looking statements are subject to risks and uncertainties.